Osteosarcoma - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Osteosarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Osteosarcoma: Overview
Osteosarcoma, also called osteogenic sarcoma, is a kind of bone cancer. Most tumors develop in the bones around the knee, either in the lower part of the thigh bone (distal femur) or the upper part of the shinbone (proximal tibia). Osteosarcoma is the most common type of bone cancer, and accounts for about 3% of cancers that happen in children. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. The upper arm bone close to the shoulder (proximal humerus) is the next most common site. Osteosarcoma tumors can be categorized as low-grade, intermediate-grade, or high-grade. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Diagnosis of osteosarcoma is based on medical history and physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy.
'Osteosarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteosarcoma Emerging Drugs
Further product details are provided in the report……..
Osteosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Osteosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.
Osteosarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Osteosarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Osteosarcoma: Overview
Osteosarcoma, also called osteogenic sarcoma, is a kind of bone cancer. Most tumors develop in the bones around the knee, either in the lower part of the thigh bone (distal femur) or the upper part of the shinbone (proximal tibia). Osteosarcoma is the most common type of bone cancer, and accounts for about 3% of cancers that happen in children. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. The upper arm bone close to the shoulder (proximal humerus) is the next most common site. Osteosarcoma tumors can be categorized as low-grade, intermediate-grade, or high-grade. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Diagnosis of osteosarcoma is based on medical history and physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy.
'Osteosarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Osteosarcoma.
This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Osteosarcoma Emerging Drugs
- Pamufetinib: Taiho Pharmaceutical
- Nivatrotamab: Y-mAbs Therapeutics
Further product details are provided in the report……..
Osteosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Osteosarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Osteosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.
Osteosarcoma Report Insights
- Osteosarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Osteosarcoma drugs?
- How many Osteosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteosarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Osteosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Taiho Pharmaceutical
- Advanced BioDesign
- Oncoinvent
- Provectus Biopharmaceuticals
- Nkarta Therapeutics
- United Therapeutics
- Guangzhou Xiangxue Pharmaceuticals
- AlaMab Therapeutics
- Y-mAbs Therapeutics
- Jiangsu Hengrui Medicine
- Exelixis
- HLB
- Chia Tai Tianqing Pharmaceutical Group
- Pamufetinib
- ABD 3001
- OI-3
- Rose Bengal sodium
- NKX 101
- Humanized dinutuximab
- TAEST 16001
- ALMB 0168
- Nivatrotamab
- Camrelizumab
- Cabozantinib
- Rivoceranib
- Famitinib
- TQ B3525
Introduction
Executive Summary
Osteosarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Osteosarcoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Pamufetinib: Taiho Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Nivatrotamab: Y-mAbs Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAEST 16001: Guangzhou Xiangxue Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
ABD 3001: Advanced BioDesign
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Osteosarcoma Key Companies
Osteosarcoma Key Products
Osteosarcoma- Unmet Needs
Osteosarcoma- Market Drivers and Barriers
Osteosarcoma- Future Perspectives and Conclusion
Osteosarcoma Analyst Views
Appendix
Executive Summary
Osteosarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Osteosarcoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Pamufetinib: Taiho Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Nivatrotamab: Y-mAbs Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAEST 16001: Guangzhou Xiangxue Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
ABD 3001: Advanced BioDesign
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Osteosarcoma Key Companies
Osteosarcoma Key Products
Osteosarcoma- Unmet Needs
Osteosarcoma- Market Drivers and Barriers
Osteosarcoma- Future Perspectives and Conclusion
Osteosarcoma Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Osteosarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Osteosarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Osteosarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Osteosarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
